Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
2.
Dermatol Ther ; 33(6): e14528, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: covidwho-917742

RESUMEN

Given the current lack of a therapeutic vaccine for coronavirus disease 2019 (COVID-19), preventive measures including mask wearing are crucial in slowing the transmission of cases. However, prolonged wearing of protective respirators, medical and fabric masks can easily generate excessive sweating, moisture and friction. Closed and warm environments heighten the skin's permeability and sensitivity to physical or chemical irritants, leading to chronic cumulative irritant contact dermatitis or, rarely, even allergic contact dermatitis. Although not representing a life-threatening condition, contact dermatitis can have a significant impact on emergency management, as it is potentially able to reduce work performance and create emotional discomfort due to the involvement of evident body areas. To minimize the skin breakdown, adherence to standards on wearing protective and safe equipments and avoidance of overprotection should be performed. At the same time, some measures of skin care are recommended. Here, we offer some tips on how to prevent and manage contact dermatitis due to masks not only in health care workers, but also in the general population during this COVID-19 outbreak.


Asunto(s)
COVID-19/prevención & control , Dermatitis por Contacto/prevención & control , Dermatitis Profesional/prevención & control , Dermatosis Facial/prevención & control , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Exposición por Inhalación/prevención & control , Máscaras/efectos adversos , Respiradores N95/efectos adversos , Cuidados de la Piel , Administración Cutánea , Corticoesteroides/administración & dosificación , Antialérgicos/administración & dosificación , Antibacterianos/administración & dosificación , COVID-19/transmisión , Dermatitis por Contacto/diagnóstico , Dermatitis por Contacto/etiología , Dermatitis Profesional/diagnóstico , Dermatitis Profesional/etiología , Dermatosis Facial/diagnóstico , Dermatosis Facial/etiología , Humanos , Exposición por Inhalación/efectos adversos , Salud Laboral , Factores Protectores , Medición de Riesgo , Factores de Riesgo , Resultado del Tratamiento
3.
Int J Dermatol ; 59(12): 1437-1449, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-892266

RESUMEN

Numerous unexplained pneumonia cases were reported to the World Health Organization (WHO) by Wuhan, China, in December 2020. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a zoonotic pathogen, came into sight, spreading coronavirus disease 2019 (COVID-19) all over the globe. Association of cutaneous signs and symptoms with COVID-19 is being studied worldwide, principally, to determine if these dermatoses can help in early recognition of SARS-CoV-2 infection. These dermatological manifestations can range from erythematous rash, urticaria to livedo reticularis, and acrocyanosis in patients of all age groups. Correspondingly, dermatologists treating COVID-19 patients, suffering from inflammatory dermatoses, with biologics or immunomodulators should exert caution and use specific protocols to adjust the doses of these medications. Prevention of person-to-person transmission of COVID-19 is being promoted universally, with the use of personal protective equipment (PPE), hand washes, and hand sanitizers around the clock. However, an array of cutaneous adverse effects such as contact dermatitis, irritant contact dermatitis, friction blisters, contact urticaria, acne, and infections are associated with the use of PPE. Extra-pulmonary manifestations of COVID-19 are still emerging in the community, and physicians and researchers are working together globally to strengthen the clinical management of these patients. Cases of COVID-19 continue to rise across the world, and an unprecedented approach has been taken to develop effective vaccines and therapeutic strategies against existing and forthcoming mutagenic strains of SARS-CoV-2.


Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/epidemiología , Dermatitis por Contacto/epidemiología , Dermatología/tendencias , Neumonía Viral/epidemiología , Enfermedades Cutáneas Infecciosas/epidemiología , Betacoronavirus/aislamiento & purificación , COVID-19 , Control de Enfermedades Transmisibles/instrumentación , Control de Enfermedades Transmisibles/métodos , Control de Enfermedades Transmisibles/normas , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/prevención & control , Dermatitis por Contacto/diagnóstico , Dermatitis por Contacto/etiología , Dermatología/normas , Higiene de las Manos/normas , Humanos , Pandemias/prevención & control , Equipo de Protección Personal/efectos adversos , Equipo de Protección Personal/normas , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/prevención & control , SARS-CoV-2 , Enfermedades Cutáneas Infecciosas/diagnóstico , Enfermedades Cutáneas Infecciosas/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA